Search research articles
Contact Us
Filters
Showing results (1-10 of 207) with videos related to
Page
of 21
Sort By:
The New England Journal of Medicine
|
December 16, 2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Alexander Niessner
Evidence-Based Medicine
|
June 29, 2012
Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment
Alexander Niessner
European Heart Journal. Cardiovascular Pharmacotherapy
|
October 17, 2017
Changing paradigms in oral anticoagulation during cardioversion in Europe
Patrick Sulzgruber, Alexander Niessner
European Heart Journal. Cardiovascular Pharmacotherapy
|
December 23, 2019
Prasugrel vs. ticagrelor after acute coronary syndrome: a critical appraisal of the ISAR-REACT 5 trial
Patrick Sulzgruber, Alexander Niessner
European Heart Journal
|
January 14, 2022
PCSK9 inhibition in patients with heart failure: neutral or harmful intervention?
Alexander Niessner, Heinz Drexel
European Heart Journal. Cardiovascular Pharmacotherapy
|
August 18, 2016
Did referral patterns for coronary angiography change in Europe? What can we learn from Denmark?
Lorenz Koller, Alexander Niessner
European Heart Journal. Cardiovascular Pharmacotherapy
|
September 11, 2019
Response to: Current opinion of the ESC Working Group on Cardiovascular Pharmacotherapy and ESC Council on Stroke
Patrick Sulzgruber, Alexander Niessner
European Heart Journal. Cardiovascular Pharmacotherapy
|
August 17, 2018
Critical appraisal of the COMPASS trial
Alexander Niessner, Stefan Agewall
Clinical Immunology (Orlando, Fla.)
|
June 13, 2009
Dendritic cells in atherosclerotic disease
Alexander Niessner, Cornelia M Weyand
European Heart Journal. Cardiovascular Pharmacotherapy
|
July 3, 2019
Critical appraisal of the AUGUSTUS trial
Thomas Gremmel, Patrick Sulzgruber, Alexander Niessner
Page
of 21
Search research articles
Search
Showing results (1-10 of 207) with videos related to
Sort By:
Page
of 21
The New England Journal of Medicine
|
December 16, 2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Alexander Niessner
Evidence-Based Medicine
|
June 29, 2012
Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment
Alexander Niessner
European Heart Journal. Cardiovascular Pharmacotherapy
|
October 17, 2017
Changing paradigms in oral anticoagulation during cardioversion in Europe
Patrick Sulzgruber, Alexander Niessner
European Heart Journal. Cardiovascular Pharmacotherapy
|
December 23, 2019
Prasugrel vs. ticagrelor after acute coronary syndrome: a critical appraisal of the ISAR-REACT 5 trial
Patrick Sulzgruber, Alexander Niessner
European Heart Journal
|
January 14, 2022
PCSK9 inhibition in patients with heart failure: neutral or harmful intervention?
Alexander Niessner, Heinz Drexel
European Heart Journal. Cardiovascular Pharmacotherapy
|
August 18, 2016
Did referral patterns for coronary angiography change in Europe? What can we learn from Denmark?
Lorenz Koller, Alexander Niessner
European Heart Journal. Cardiovascular Pharmacotherapy
|
September 11, 2019
Response to: Current opinion of the ESC Working Group on Cardiovascular Pharmacotherapy and ESC Council on Stroke
Patrick Sulzgruber, Alexander Niessner
European Heart Journal. Cardiovascular Pharmacotherapy
|
August 17, 2018
Critical appraisal of the COMPASS trial
Alexander Niessner, Stefan Agewall
Clinical Immunology (Orlando, Fla.)
|
June 13, 2009
Dendritic cells in atherosclerotic disease
Alexander Niessner, Cornelia M Weyand
European Heart Journal. Cardiovascular Pharmacotherapy
|
July 3, 2019
Critical appraisal of the AUGUSTUS trial
Thomas Gremmel, Patrick Sulzgruber, Alexander Niessner
Page
of 21